This meta-analysis (s=5, n=158) of classic psychedelic effects on empathy using the Multifaceted Empathy Test (MET) finds significant enhancement of explicit and implicit emotional empathy, with no effect on cognitive empathy. The analysis covers studies up to November 2023 examining LSD, psilocybin, and ayahuasca.
This meta-analysis investigates the effect of classic psychedelic drugs on empathy and focuses on cognitive and emotional empathy measured using the Multifaceted Empathy Test (MET). Empathy entails the ability to understand and share the feelings of another and is a significant component of social interaction. Several studies have examined the effects of psychedelic drugs such as LSD, psilocybin and ayahuasca on empathy, yet their overall effect has not been studied so far. In this meta-analysis, we reviewed data from studies up to November 2023 with the aim of examining the effects of various psychedelic drugs on empathic abilities broadly. Our findings suggest that classical psychedelics significantly enhance explicit and implicit emotional empathy without affecting measures of cognitive empathy. The results emphasize the need to continue testing the therapeutic potential of classic psychedelic drugs.
Empathy is a multifaceted social-cognitive capacity encompassing cognitive empathy (understanding another's mental states) and emotional empathy (sharing another's feelings), with the latter often divided into implicit (automatic arousal) and explicit (deliberate self-report) components. Earlier experimental studies reported mixed findings on how classical psychedelics—principally LSD, psilocybin and ayahuasca, all 5-HT2A receptor agonists—affect social cognition: some work found increases in emotional empathy and sociality, while effects on cognitive empathy have been inconsistent. No previous meta-analysis had synthesised results across a single standardised task to clarify the overall pattern of effects across these substances. In response to that gap, Olami and colleagues conducted a PRISMA-guided meta-analysis restricted to studies that used the Multifaceted Empathy Test (MET), a validated task that provides measures of cognitive empathy (accuracy in identifying emotions from photos), explicit emotional empathy (self-report ratings) and implicit emotional empathy (arousal ratings). By limiting synthesis to one task, the researchers aimed to improve comparability across studies that varied in drug type, dose, setting and timing of assessment, and to estimate the pooled effects of LSD, psilocybin and ayahuasca on the MET-derived empathy outcomes.
Papers cited by this study that are also in Blossom
Uthaug, M. V., Mason, N. L., Toennes, S. W. et al. · Psychopharmacology (2021)
Kiraga, M. K., Mason, N. L., Uthaug, M. V. et al. · Frontiers in Pharmacology (2021)
Preller, K. H., Vollenweider, F. X. · Frontiers in Psychiatry (2019)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
The authors searched PubMed (Medline), PsycINFO and Scopus from inception to November 2023 using keywords for classical psychedelics (LSD, psilocybin, ayahuasca, DMT and related terms) combined with empathy- and MET-related terms. Eligible studies were peer-reviewed, English-language, original articles on healthy human participants that administered at least one dose of LSD, psilocybin or ayahuasca and reported MET outcomes. Exclusions comprised reviews, non-human studies, retrospective self-report assessments of prior psychedelic use, and non–full-text items (letters, abstracts, conference papers). No exclusions were applied for participant age, sex, drug dose, administration route or study size. Data extracted included study identifiers, sample sizes and demographics, drug type and dose, and MET outcome means and standard deviations. When means and SDs were not reported, effect sizes were estimated by digitising figures, or calculated from reported F or p values. The MET outcomes analysed were: cognitive empathy (accuracy measured as percentage correct), explicit emotional empathy (self-report ratings), and implicit emotional empathy (arousal ratings). Positive and negative stimulus sub-analyses were performed where data permitted. Meta-analyses used Hedges' g (a small-sample bias–corrected standardised mean difference, interpreted with Cohen's D benchmarks) and were implemented using the metafor package in RStudio (version 2023.06.1) and Comprehensive Meta-Analysis (Version 3.3.070). A random-effects framework was applied given expected between-study variability. Heterogeneity was quantified with the Q statistic and I2 index, with I2 values of ~25%, 50% and 75% taken as low, moderate and high heterogeneity. Small-study bias was assessed with Egger's regression test and funnel-plot–based trim-and-fill analyses. Influence diagnostics and sensitivity analyses were used to identify outliers. Risk-of-bias assessment was performed in duplicate: the revised Cochrane RoB 2 tool for randomized trials and ROBINS-I for non-randomised intervention studies, with disagreements resolved by discussion.
Five studies contributed data for the primary MET analyses (combined overall sample n = 158). For cognitive empathy (accuracy), classical psychedelics showed no statistically significant pooled effect versus placebo or baseline (k = 5, Hedges' g = -0.1153, 95% CI -2.0316 to 1.8010, p = 0.9061, Z = -0.1179). Between-study heterogeneity was high and statistically significant (Q = 36.7194, df = 5, I2 = 87.34%, p < 0.0001). Explicit emotional empathy increased under classical psychedelics compared with placebo or baseline (k = 5, combined n = 158, Hedges' g = 0.7921, 95% CI 0.1786 to 1.4057, p = 0.0114, Z = 2.5304). Heterogeneity was negligible for this outcome (Q = 1.1867, df = 5, I2 = 0.00%, p = 0.9461). Tests for small-study bias were not significant (Egger's p = 0.7800), although a trim-and-fill analysis estimated two potentially missing studies on the right; influence diagnostics identified no overall outliers for the pooled explicit-empathy estimate. Implicit emotional empathy ratings were also elevated following classical psychedelic administration (k = 5, combined n = 158, Hedges' g = 0.7635, 95% CI -0.0191 to 1.5461, p = 0.0500, Z = 1.9121). Between-study heterogeneity was negligible (Q = 0.4442, df = 5, I2 = 0.00%, p = 0.9940). Egger's test did not indicate small-study bias (p = 0.6427), though trim-and-fill suggested three possibly missing studies on the right; influence diagnostics did not flag outliers for the overall implicit-empathy analysis. Analyses stratified by stimulus valence yielded the following summaries. For cognitive empathy, neither positive nor negative stimuli produced significant effects (positive: k = 3, n = 106, Hedges' g = 0.7794, 95% CI -0.4135 to 1.9722, p = 0.2003; negative: k = 3, n = 106, Hedges' g = 0.7432, 95% CI -0.4431 to 1.9295, p = 0.2195); heterogeneity for these sub-analyses was low (I2 = 0.00%). For explicit emotional empathy by valence, positive stimuli were associated with a large pooled effect (k = 3, n = 109, Hedges' g = 1.6016, 95% CI -1.0784 to 4.2815, p = 0.0415), but between-study heterogeneity was substantial and significant (Q = 8.4933, I2 = 78.58%, p = 0.0143) and Egger's test indicated possible small-study bias (p = 0.0391); influence diagnostics identified the Dolder et al. study as an influential outlier. For negative stimuli, explicit emotional empathy was also elevated (k = 3, n = 109, Hedges' g = 0.8142, 95% CI -0.3727 to 2.0010, p = 0.0078) with low heterogeneity (I2 = 0.00%) and no clear publication-bias signal. Implicit-empathy valence analyses showed increases for both positive (k = 4, n = 128, Hedges' g = 1.0934, 95% CI -0.0528 to 2.2397, p = 0.0415; I2 = 15.32%) and negative stimuli (k = 5, n = 158, Hedges' g = 0.9082, 95% CI -0.0189 to 1.8353, p = 0.0500; I2 = 0.00%). One influential outlier for implicit positive stimuli was again identified as Dolder et al. Publication-bias tests were generally non-significant across outcomes except for explicit positive stimuli, where Egger's test suggested bias. Risk-of-bias assessment found heterogeneity in study quality. Using RoB 2 on three randomized trials, two were judged low risk and one (Uthaug et al.) high risk due to deviations from intended interventions and reliance on facilitator-administration in retreat settings. ROBINS-I applied to two nonrandomised studies rated Mason et al. as low-to-moderate risk and Kiraga et al. as having a serious overall risk owing to confounding, selection bias, and missing-data concerns.
Olami and colleagues interpret their pooled findings as evidence that classical psychedelics tend to enhance emotional components of empathy—both explicit self-reported empathy and implicit arousal responses—while producing no consistent change in cognitive empathy as measured by the MET. They situate these results alongside prior experimental reports of increased emotional empathy following LSD, psilocybin and ayahuasca. The authors propose several plausible mechanisms to explain heightened emotional empathy. Perceptual alterations under psychedelics, including changes in bodily perception and reports of ego dissolution (a reduced sense of separateness from others), might blur self–other boundaries and thereby increase emotional resonance. Neurophysiological correlates invoked include reductions in posterior alpha power previously linked to heightened emotional empathy. Personality change provides another possible pathway: psychedelics have been associated with increases in openness, and higher openness correlates with greater empathy. Comparisons are drawn to MDMA, which also enhances emotional empathy and modulates serotonergic systems; the authors note that LSD's broad receptor profile (including dopaminergic binding) and ayahuasca's additional MAOI and β-carboline constituents (e.g. harmine) could produce distinct effects, even though the meta-analysis grouped substances on the basis of shared 5-HT2A agonism. They further cite a pharmacological observation that ketanserin (a 5-HT2A antagonist) did not fully block LSD-associated increases in emotional empathy, implying additional receptor mechanisms may be involved. The paper acknowledges important limitations that constrain interpretation. Chief among these is the small number of eligible studies (five), which reduces statistical power and the generalisability of pooled estimates. Heterogeneity in substances, doses, settings (laboratory versus retreat/ceremony), timing of assessment and study designs contributes further uncertainty. Risk-of-bias assessments showed variability across studies, from low to high/serious risk, particularly where interventions occurred in uncontrolled retreat contexts or where self-selection and missing-data issues were present. Measurement considerations are also noted: the MET may not capture all aspects of cognitive empathy, and other tasks (e.g. Reading the Mind in the Eyes Test, MASC, FERT) have produced inconsistent findings across studies. Given these caveats, the authors recommend future research employ more rigorous, standardised methodologies: placebo-controlled, properly randomised designs with consistent dosing and administration, objective measures and neuroimaging to probe neural mechanisms, and longitudinal and clinical-population studies to evaluate therapeutic potential. They also highlight the value of comparing different empathy measures and examining individual differences in subjective responses. Finally, the investigators highlight the meta-analysis' strengths—use of a single standardised task (MET) to improve comparability and inclusion of varied real-world settings—which they argue provides initial, ecologically valid evidence that classical psychedelics may selectively enhance emotional empathy and warrants further investigation.
This meta-analysis investigates the effect of classic psychedelic drugs on empathy and focuses on cognitive and emotional empathy measured using the Multifaceted Empathy Test (MET). Empathy entails the ability to understand and share the feelings of another and is a significant component of social interaction. Several studies have examined the effects of psychedelic drugs such as LSD, psilocybin and ayahuasca on empathy, yet their overall effect has not been studied so far. In this meta-analysis, we reviewed data from studies up to November 2023 with the aim of examining the effects of various psychedelic drugs on empathic abilities broadly. Our findings suggest that classical psychedelics significantly enhance explicit and implicit emotional empathy without affecting measures of cognitive empathy. The results emphasize the need to continue testing the therapeutic potential of classic psychedelic drugs. Empathy is a complex psychological construct crucial for human interaction and communication. It encompasses various dimensions, including cognitive and emotional empathy in implicit and explicit forms. Empathy is defined as the understanding of a person from their frame of reference rather than one's own or vicariously experiencing that person's feelings, perceptions, and thoughts. Empathy towards others can aid in creating more meaningful relationships and enhance our social interactions. Cognitive empathy, also known as the Theory of Mind, involves the mental capacity to comprehend and process the thoughts and emotions of others, enabling us to grasp different perspectives and foster mutual understanding and respect in diverse interactions. Emotional empathy, on the other hand, goes beyond mere understanding to an emotional resonance, allowing us to share in the joy, sorrow, excitement, or pain of others, and is crucial for building emotional bonds and providing comfort and support. Emotional empathy can be further divided into implicit and explicit emotional empathy. Implicit empathy, often referred to as "arousal, " includes the automatic, unconscious aspect of emotional empathy in which the sharing of emotions arouses the observing individual. In contrast, explicit emotional empathy is a deliberate and conscious process requiring mental effort and conscious processing, enabling us to respond appropriately and empathetically toward other people's emotions. In recent years, the field of social cognition has faced challenges due to the heterogeneous and sometimes inconsistent use of terminology, particularly in the context of concepts like empathy and mental state attribution. As highlighted by Quesque et al., there is a growing movement towards harmonizing these terms to improve clarity and comparability across studies and fields. While Quesque et al.advocates for the use of standardized terms such as "mentalizing" to encompass what is often referred to as "cognitive empathy", our study adheres to the terminology used in the specific task we are investigating. This choice is driven by the need for consistency in the interpretation of our findings within the context of the MET task. It is possible that levels of empathy may be influenced by various psychological and biological interventions. One such intervention, pertains to the use of classical psychedelics that can enhance empathic abilities. In recent years, researchers have discovered an interest in the effects of psychedelic drugs on social cognition in general and empathy in particular, and research has been done on the impact of these drugs on various types of empathyClassical psychedelics, including Lysergic acid diethylamide (LSD), psilocybin, and ayahuasca, are all agonists at the 5-HT2A receptor, a serotonin receptor subtype. These substances have shown potential in addressing various psychiatric conditions, including depression and anxiety, by breaking rigid mental patterns that are resistant to change. LSD is derived from the ergot mushroom,
From inception up to November 2023, a search for relevant articles was conducted in the PubMed (Medline), PsycINFO, and Scopus bibliographic databases using specific keywords: "LSD" OR "ayahuasca" OR "psychedelic" OR "lysergic acid diethylamide" OR "Psilocybin" OR "DMT" OR "Dimethyltryptamine" AND "empathy" OR "emotion" OR "social cognition" OR "emotional empathy" OR "cognitive empathy" OR "implicit" OR "explicit" OR "implicit emotional empathy" OR "explicit emotional empathy", AND "MET" OR "multifaceted empathy test". After a full-text review, if a study was deemed eligible, its reference list was manually scrutinized for other relevant studies. Initially, duplicate records were eliminated, and subsequently, the titles and abstracts of the remaining publications were assessed. Any publications that did not meet the inclusion criteria were excluded. The remaining publications were further evaluated by thoroughly reviewing the full text. The inclusion criteria were then applied again. To be considered for inclusion, studies had to meet the following eligibility criteria: (1) they had to be original, peer-reviewed, full-text articles written in English; (2) they had to involve healthy human participants; (3) they had to include a single-dose or more of LSD or ayahuasca or psilocybin intervention; and (4) they had to include an outcome(s) related to the MET tasks, provided that they met the eligibility criteria mentioned above. Studies were excluded if they were reviews and meta-analyses, included non-human subjects, assessed previous classic psychedelics users retrospectively through self-report questionnaires, or were letters, comments, abstracts, or conference papers. There were no exclusions based on the age or sex of the subjects, classic psychedelics dose or frequency, administration routes, or study size (Fig.).
The recorded variables included general information, such as the study's authors, year of publication, number of subjects, and demographic variables, such as age, gender, and classic psychedelic dosage and kinds of substance (Table). For the calculation of effect sizes, means and standard deviations (SD) of the MET task results were collected. If this information was not available in the publication or provided by the authors, effect sizes were estimated using one of the following methods: (1) by extracting mean and SD from published figures (using PlotDigitizer software, available at), (2) based on F values, or (3) based on p values.
The meta-analyses were conducted using the 'metaphor' packagein RStudio version 2023.06.1 and Comprehensive Meta-Analysis (Version 3.3.070). We gathered data for the MET task, which involved obtaining means and standard deviations for three variables: (1) cognitive empathy, which measured the accuracy (measured in percentage) in discerning emotions portrayed in the photos; (2) explicit emotional empathy, reflecting the participants' ratings indicating their level of self-report explicit empathy towards the person in the photo; and (3) implicit emotional empathy, indicating the arousal levels experienced while viewing the photos. In addition, where available we separately analyzed positive and negative stimuli. Hedges' g was used to measure effect size. Hedges' g corrects for sample size bias and is interpreted according to Cohen's D guidelines (0.2 for small effect, 0.5 for medium effect, and 0.8 for large effect). Q statistic was used to evaluate heterogeneity across studies based on the random effects model, as significant heterogeneity is expected in meta-analyses of observational studies. Q assesses the amount of observed dispersion, and a statistically significant Q suggests that the studies do not share a common true effect size. The I2 index was used to assess the proportion of total variability in effect size estimates, with I2 values of approximately 25%, 50%, and 75% indicating low, moderate, and high heterogeneity, respectively. Publication bias due to small study bias was quantitatively tested using Egger's regression testfor each outcome. An Egger's test with a P value less than 0.05 indicated a small study bias. Outlier and influence diagnostics were conducted to determine the impact of any outliers, and sensitivity re-analyses were performed without any identified outliers.
This study contains a meta-analysis of both randomized and nonrandomized studies of intervention. Two reviewers (L.P.A and I.L) assessed each study independently with conflicts resolved by discussion. We assessed the risk of bias of included randomized studies using the revised Cochrane risk-of-bias tool for randomized trials (RoB2 tool)which scores the risk of bias in five domains namely: randomization process, deviations from the intended interventions, missing outcome data, measurement of the outcome and selection of the reported result. The overall risk of bias was determined based on the reviewers' judgement for each of the domains. An overall "low risk of bias" score is given when the study is judged to be at low risk of bias for all domains. An overall "some concerns" score is given when the study is judged to raise some concerns in at least one domain, but not to be at high risk for any domain. An overall "high risk of bias" score is given when the study is judged to be at high risk of bias in at least one domain. Three studies were assessed using the Rob2 tool: Dolder et al., Pokorny et al.and Uthaug et al.. The Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) toolwas used to assess the methodological quality and risk of bias in the included non-randomized studies. ROBINS-I evaluates bias across seven domains: confounding, selection of participants, classification of interventions, deviations from intended interventions, missing data, measurement of outcomes, and selection of the reported result. Each domain is rated as having low, moderate, serious, or critical risk of bias, allowing for a comprehensive assessment of the overall risk of bias in each study. This approach ensures a systematic evaluation of potential biases that could impact the validity of the study findings. Two studies were assessed using the ROBINS-I tool: Kiraga et al.and Mason et al..
Classical psychedelics did not yield a statistically significant effect on cognitive empathy accuracy measures compared to placebo or baseline measures across the included studies (studies: n = 5 combined overall sample size: n = 158, Hedges' g= -0.1153 95% CI from -2.0316 to 1.8010, p = 0.9061, Z-value=-0.1179). Betweenstudies heterogeneity was significant (Q = 36.7194, df = 5, I 2 = 87.34%, p < 0.0001) (Fig.).
No publication bias was found due to a small study effect, as indicated by Egger's regression test (p = 0.5628). The funnel plot asymmetry tests, including regression test (z = 0.5786, p = 0.5628) and rank correlation test (Tau = 0.1380, p = 0.7021), did not indicate significant publication bias or small-study effects. The trim-and-fill analysis, aiming to assess the potential impact of publication bias on the meta-analysis, revealed an estimated number of missing studies on the right side of 3, with a standard error (SE) of 1.5812. This suggests that the asymmetry observed in the funnel plot, indicative of potential publication bias, could have affected other studies. Influence diagnostics did not identify any outliers.
The effect of positive stimuli on cognitive empathy accuracy measures was not statistically significant compared to placebo or baseline measures across the included studies (k = 3, combined overall sample size: n = 106, Hedges' g = 0.7794, 95% CI from -0.4135 to 1.9722, p = 0.2003, Z-value = 1.2806). Between-study heterogeneity was not significant (Q(df = 2) = 0.6644, I 2 = 0.00%, p = 0.7173). (Fig.).
No publication bias was detected due to a small study effect, as indicated by Egger's regression test (p = 0.9097). The funnel plot asymmetry test, including the regression test (t = -0.1428, df = 1), did not indicate significant publication bias or small-study effects. The trim-and-fill analysis estimated no missing studies on the right side (SE = 1.4967), suggesting that the symmetry observed in the funnel plot does not reflect potential publication bias. Influence diagnostics did not identify any significant outliers.
The effect of negative stimuli on cognitive empathy accuracy measures was not statistically significant compared to placebo or baseline measures across the included studies (k = 3, combined overall sample size: n = 106, Hedges' g = 0.7432, 95% CI from -0.4431 to 1.9295, p = 0.2195, Z-value = 1.2279). Between-study heterogeneity was not significant (Q(df = 2) = 0.7958, I 2 = 0.00%, p = 0.6717). (Fig.).
No publication bias was detected due to a small study effect, as indicated by Egger's regression test (p = 0.8232). The funnel plot asymmetry test, including the regression test (t = -0.2851, df = 1), did not indicate significant publication bias or small-study effects. The trim-and-fill analysis estimated no missing studies on the right side (SE = 1.4967), suggesting that the symmetry observed in the funnel plot does not reflect potential publication bias. Influence diagnostics did not identify any significant outliers.
Classical psychedelics were associated with an increase in explicit emotional empathy compared to placebo or baseline measures across the included studies (studies: n = 5; combined overall sample: n = 158, Hedges' g = 0.7921, 95% CI from 0.1786 to 1.4057, p = 0.0114, Z-value = 2.5304). Between-studies heterogeneity was non-significant (Q = 1.1867, df = 5, I 2 = 0.00%, p < 0.9461) (Fig.).
There was no significant publication bias. This is evidenced by the absence of a small study effect, as indicated by Egger's regression test (p = 0.7800). The results from the funnel plot asymmetry tests, including the regression test (z = -0.2793, p = 0.7800) and the rank correlation test (Kendall's tau = -0.2760, p = 0.4442), consistently do not show significant publication bias or small-study effects. Influence diagnostics did not identify any outliers. The trim-and-fill analysis, aiming to assess the potential impact of publication bias on the meta-analysis, revealed an estimated number of missing studies on the right side of 2, with a standard error (SE) of 1.7837. This suggests that the asymmetry observed in the funnel plot, indicative of potential publication bias, could have affected other studies. Influence diagnostics did not identify any outliers.
The effect of positive stimuli were associated with an increase in explicit empathy accuracy measures compared to placebo or baseline measures across the included studies (k = 3, combined overall sample size: n = 109, Hedges' g = 1.6016, 95% CI from -1.0784 to 4.2815, p = 0.0415, Z-value = 1.1713). Between-study heterogeneity was significant (Q(df = 2) = 8.4933, I 2 = 78.58%, p = 0.0143) (Fig.).
A significant publication bias was detected, as indicated by Egger's regression test (p = 0.0391). The funnel plot asymmetry test, including the regression test (t = 16.2536, df = 1), indicated significant publication bias or smallstudy effects. The trim-and-fill analysis estimated no missing studies on the left side (SE = 1.4967), suggesting that the asymmetry observed in the funnel plot may reflect potential publication bias. Influence diagnostics identified one influential outlier, specifically in the study by Dolder et al..
The effect of negative stimuli were associated with an increase in explicit empathy accuracy measures compared to placebo or baseline measures across the included studies (k = 3, combined overall sample size: n = 109, Hedges' g = 0.8142, 95% CI from -0.3727 to 2.0010, p = 0.0078, Z-value = 1.3445). Between-study heterogeneity was not significant (Q(df = 2) = 0.8966, I 2 = 0.00%, p = 0.6387) (Fig.).
No significant publication bias was detected, as indicated by Egger's regression test (p = 0.3570). The funnel plot asymmetry test, including the regression test (t = 1.5924, df = 1), did not indicate significant publication bias or small-study effects. The trim-and-fill analysis estimated no missing studies on the left side (SE = 1.4967), suggesting that the symmetry observed in the funnel plot does not reflect potential publication bias. Influence diagnostics did not identify any significant outliers.
Classical psychedelics were associated with an increase in implicit emotional empathy ratings compared to placebo within the analyzed studies (studies: n = 5; combined overall sample: n = 158, Hedges' g = 0.7635, 95% CI from -0.0191 to 1.5461, p = 0.05, Z-value = 1.9121). The analysis revealed non-significant between-studies heterogeneity (Q = 0.4442, df = 5, I 2 = 0.00%, p < 0.9940) (Fig.).
Non significant publication bias was found, due to a small study effect as indicated by Egger's regression test (p = 0.6427). The funnel plot asymmetry tests, including the regression test (z = -0.4639, p = 0.6427) and The Rank Correlation Test for Funnel Plot Asymmetry (Kendall's tau of -0.2000 with a p-value of 0.7194), did not indicate significant publication bias or small-study effects. The trim-and-fill analysis, aiming to assess the potential impact of publication bias on the meta-analysis, revealed an estimated number of missing studies on the right side of 3, with a standard error (SE) of 1.6385. This suggests that the asymmetry observed in the funnel plot, indicative of potential publication bias, could have affected other studies. Influence diagnostics did not identify any outliers.
The effect of positive stimuli were associated with an increase in implicit empathy accuracy measures compared to placebo or baseline measures across the included studies (k = 4, combined overall sample size: n = 128, Hedges' g = 1.0934, 95% CI from -0.0528 to 2.2397, p = 0.0415, Z-value = 1.8696). Between-study heterogeneity was not significant (Q(df = 3) = 3.7139, I 2 = 15.32%, p = 0.2941) (Fig.).
No significant publication bias was detected, as indicated by Egger's regression test (p = 0.1890). The funnel plot asymmetry test, including the regression test (t = 1.9607, df = 2), did not indicate significant publication bias or small-study effects. The trim-and-fill analysis estimated no missing studies on the left side (SE = 1.3802), suggesting that the asymmetry observed in the funnel plot does not reflect potential publication bias. Influence diagnostics identified one influential outlier, specifically in the study by Dolder et al..
The effect of negative stimuli were associated with an increase in implicit empathy accuracy measures compared to placebo or baseline measures across the included studies (k = 5, combined overall sample size: n = 158, Hedges' g = 0.9082, 95% CI from -0.0189 to 1.8353, p = 0.0500, Z-value = 1.9199). Between-study heterogeneity was not significant (Q(df = 4) = 0.9942, I² = 0.00%, p = 0.9107) (Fig.).
No significant publication bias was detected, as indicated by Egger's regression test (p = 0.4036). The funnel plot asymmetry test, including the regression test (t = 0.9699, df = 3), did not indicate significant publication bias or small-study effects. The trim-and-fill analysis estimated no missing studies on the left side (SE = 1.5965), suggesting that the symmetry observed in the funnel plot does not reflect potential publication bias. Influence diagnostics did not identify any significant outliers.
The risk of bias (Fig.) was assessed using the RoB 2 tool across three studies included in this analysis and found low risk of bias for two studies and a high risk of bias for one study. Specifically, Dolder et al.exhibited a low risk of bias across all domains. The robust double-blind, placebo-controlled, crossover design and meticulous execution contributed to this favorable assessment. Pokorny et al.was judged to have some concerns regarding the randomization process, primarily due to a lack of detailed reporting on baseline characteristics, which raised questions about the comparability of the groups. However, the study maintained a low risk of bias in all other domains, suggesting that the overall results are likely reliable despite these concerns. In contrast, Uthaug et al.was found to have a high overall risk of bias. While randomization was adequately handled, significant deviations from intended interventions were noted, primarily due to variability in dosages across retreats and a lack of control by the research team over the intervention environment (which was administered by facilitators). Additionally, concerns regarding outcome measurement, particularly the reliance on self-reported data in a psychedelic study, further contributed to the high-risk rating (Table). The ROBINS-I assessment was used across two studies included in this analysis and found a low to moderate risk of bias for one study and a serious risk of bias for the other study. The tool categorized Mason et al.as having a low to moderate risk of bias. While the study had moderate risks related to confounding and participant selection-due to the volunteer nature of the psilocybin retreats-the classification of interventions and measurement of outcomes were well-controlled and consistent. The study experienced some dropouts, but the overall impact on results was mitigated using validated measures and comprehensive outcome reporting (Table). For Kiraga et al., the analysis identified a serious overall risk of bias. The study faced substantial issues, including serious risks due to confounding variables, selection bias from self-selected participants, and variability in intervention application due to differences in facilitator practices and settings. The study also reported significant dropout rates, with unclear handling of missing data, which exacerbates concerns. Despite using validated measurement tools and reporting all relevant outcomes, the significant issues in confounding, selection, and intervention application suggest that the study's results should be interpreted with caution.
The results of this meta-analysis indicate that classical psychedelics are associated with an increase in explicit and implicit emotional empathy and are not associated overall with any change in cognitive empathy (no significant increase or decrease was demonstrated in the meta analysis). Our research aligns with previous studies showing that psychedelics increase emotional empathy. The findings suggest that classic psychedelics may increase the emotional components of empathy, while further research is necessary to understand their impact on the cognitive components of empathy. There are several potential interpretations for the demonstrated increase in emotional empathy. When using psychedelic substances, users have reported changes in perception, including hallucinations, subjective perception of time and space and perception of the body. Specifically, distorted perception of the body might lead to blurring of the boundaries between self and other, which might lead to an increased ability to share the emotions of another, i.e., emotional empathy. On a related note, psychedelic drugs can lead to a feeling of ego dissolution. Ego dissolution entails the dismantling of the experience of the egoand is accompanied by the lowering of the boundaries between the self and other people. At the neural level, ego dissolution has been linked to reduced alpha power in the posterior cortex, which has been associated with increased emotional empathy levels. It is possible that due to the effect of psychedelic drugs on the dissolution of the ego, there may be an effect on emotional empathy, and this is due to an increase in the ability to merge with another person and, through that, to understand and share the feelings of others. Another mechanism through which classical psychedelics could affect emotional empathy is personality traits. Psychedelics were found to increase the personality trait of openness, and higher levels of openness have been associated with higher levels of general empathy. Thus, it is possible that through an increase in openness to the experience of other individuals, the users can become more emotionally empathic to their surroundings. To get a deeper understanding of the relationship between psychedelics, empathy, and personality traits, further research is necessary. A similar pattern of results was also observed with 3,4-methylenedioxymethamphetamine (MDMA), a compound with strong empathogenic properties. Specifically, MDMA was also found to enhance emotional empathy. Its action as a serotonin-enhancing agent shares common neurochemical pathways with classical psychedelics' neural effects. This similarity suggests a potential overlap in how these substances modulate social and emotional processing, specifically through the enhancement of serotonin that affects emotional empathy. Interestingly, when a 5-HT2a receptor antagonist (Ketanserin) was administered with 200 mg of LSD, emotional empathy was still elevated compared to placebo, which points to a different mechanism that might be involved in the LSD associated increase of emotional empathy other than the 5HT2A receptor. Indeed, LSD demonstrates a high affinity for nearly all 14 serotonin receptors. In addition, LSD binds to dopamine receptors such as D1Future research should closely discern the effects of different serotonin and dopamine receptors that underpin this increase in emotional empathy. Our meta-analysis groups together different substances: LSD, psilocybin and ayahuasca. While our metaanalysis provides valuable insights into the effects of classical psychedelics on empathy, it is important to acknowledge the limitations and differences in their mechanisms of action. LSD, psilocybin, and ayahuasca all act on the 5-HT2A receptor but have different pharmacological profiles. For example, LSD has increased dopaminergic activity compared to psilocybin, potentially affecting cognitive and emotional processes differently. Psilocybin and ayahuasca primarily affect serotonergic pathways, with ayahuasca also involving monoamine oxidase inhibitors (MAOIs). In addition, the β-carbolines found in ayahuasca, such as harmine, interact with glutamatergic and dopaminergic systems. This sets ayahuasca apart from other psychedelics. Harmine, specifically, also inhibits the enzyme monoamine oxidase (MAO), which not only extends the psychoactive effects of DMT but may also contribute to its antidepressant and neuroprotective properties. Additionally, LSD's interaction with dopamine D2 receptors could explain its distinct cognitive and emotional effects compared to other psychedelics, adding another layer of complexity to its impact on empathy. Despite these differences, we grouped these substances to provide a comprehensive overview of their general effects on empathy due to their common 5-HT2A receptor agonism. Future research should explore the specific mechanisms and differential effects of each psychedelic, particularly the unique contributions of serotonergic and dopaminergic systems. The results of this meta analysis suggest that classical psychedelics are not associated with either an increase or decrease in cognitive empathy. We did not demonstrate an effect of classical psychedelics on cognitive empathy. This could be due to the small number of studies included in this meta analysis, yet perhaps the task used (MET) might not capture the intricate effects of classical psychedelics on cognitive empathy. Other than the MET, there are several metrics that are commonly used to investigate the effects of psychedelics on empathy, particularly cognitive empathy. These include Reading the Mind in the Eyes Test (RMET), the Movie for the Assessment of Social Cognition (MASC)and various versions of the Facial Emotion Recognition Test (FERT). The RMET assesses cognitive empathy by measuring the ability to infer others' mental states from images of their eyes. For example, a study found that psilocybin decreases the ability to interpret negative emotions in the RMET. The
The study used a double-blind, placebocontrolled, crossover design, with balanced order randomization. Both groups received the intended intervention (LSD or placebo) under tightly controlled conditions. The study reported minor data loss (2/24 participants due to technical issues), unlikely to influence outcomes significantly. The outcomes were measured objectively using standardized tasks and tools, with blinding maintained throughout. The study appears to have reported all relevant outcomes, and the analysis seems consistent with the planned methods. Overall, the study exhibits a low risk of bias across the key domains. The randomization and blinding processes were robust, and the analysis appears comprehensive and consistent with the study design. There is an area where the study lacks detailed information (e.g., randomization process) which leads to an overall judgment of "Some concerns" for the risk of bias. However, the study appears to have taken reasonable steps to minimize bias in most domains, suggesting that the results are likely reliable despite these concerns.
The study involved random assignment of participants to either the ayahuasca or placebo group, which was managed by the host organization. There is no mention of any significant issues in the randomization process, and the baseline characteristics of participants between the groups appear balanced. Several factors contribute to a higher risk in this domain. The interventions were administered by facilitators of the retreat rather than the research team, and the procedures for preparing the ayahuasca and placebo were not standardized across all locations. Additionally, the research team had no control over the administration of doses or the environment in which the intervention took place. The study also reports that the contents and storage of the capsules were not well-documented, which introduces potential variability and risk. The study does not report any significant missing data, and all participants seem to have been accounted for in the final analysis. Several of the outcomes were based on self-report measures, which are subject to bias, especially in a study involving psychedelic substances where participants may have expectations about the effects. However, the study used validated questionnaires and tasks for their other outcomes. The study appears to have reported on all pre-specified outcomes and used appropriate statistical analyses. There are no indications of selective reporting based on the provided information. While the study has strengths in randomization and the comprehensiveness of outcome reporting, the significant deviations from intended interventions and the concerns over the measurement of outcomes (self-report) contribute to an overall high risk of bias. The lack of control over intervention standardization and potential influence of participant and facilitator biases are key issues that impact the reliability of the findings. Table. Assessment of risk of bias of individual studies (using the RoB-2 for RCTs). MASC is a test with several video clips featuring social situations that require mentalizing abilities. Thus, this test is focusing on cognitive empathy. Long term use of MDMA (as measured in hair strands) was associated with higher cognitive empathy levels as measured with the MASC. The FERT measures identification of emotions from facial expressions with the ability to measure the level of intensity required to identify the emotion. LSD impairs the recognition of negative emotions like fear and sadness while enhancing the recognition of positive emotions such as happiness measured with the FERT. In contrast, a pilot study found no effects of ayahuasca on recognition of emotions from facial expressions using a version of the FERTTherefore, future studies should consider comparing different measures of cognitive empathy to further deepen our understanding of the effects of classical psychedelics on cognitive empathy. As detailed above, several studies found differences in the effects of psychedelics on positive and negative stimuli in various empathy tasks. We therefore examined the differential effect of positive and negative stimuli here on changes in cognitive and emotional empathy. Our additional analysis yielded intriguing results. For cognitive empathy, we found that classical psychedelics neither increased nor decreased performance, regardless of whether the stimuli were positive or negative. This suggests that the ability to accurately identify others' states remains stable under the influence of these substances, irrespective of the emotional valence of the content being processed. In line with this result, both implicit and explicit emotional empathy were unaffected by the valence of the stimuli and were elevated by classical psychedelics for both positive and negative stimuli. This indicates that the emotional empathy-enhancing effects of classical psychedelics are robust across different emotional contexts. Future research could explore whether this valence-independent enhancement of emotional empathy translates to improved interpersonal relationships and social functioning in both clinical and non-clinical populations. This meta-analysis has several limitations that must be acknowledged, primarily the small sample size of only five studies. The limited number of studies impacts the robustness and generalizability of our findings, as conclusions drawn from such a small sample may not fully represent the broader effects of classical psychedelics on empathy. Additionally, the heterogeneity observed across the included studies suggests variability in experimental protocols, including differences in drug types, doses, settings (e.g., laboratory vs. retreat environments), and the timing of task administration relative to psychedelic ingestion. These variations may introduce inconsistencies in the results, complicating the ability to draw definitive conclusions. We chose to conduct a risk of bias analysis in this meta-analysis to ensure the robustness and reliability of our findings. Given the variability in study designs, participant characteristics, and experimental conditions, it was crucial to assess the potential biases that could influence the results. By evaluating the risk of bias, we aimed to identify and address any methodological weaknesses in the included studies, providing a more accurate interpretation of the overall effects of classical psychedelics on empathy. We conducted a Risk of Bias assessment using the RoB 2 and ROBINS-I tools. This analysis reveals a range of concerns across the studies included in this meta-analysis, emphasizing the need for careful interpretation of the findings. Overall, studies exhibited a spectrum of bias risks, from low to high, affecting the reliability of their results. Studies with low risk of bias benefited from rigorous methodological approaches, such as double-blind, placebo-controlled designs and well-defined interventions. However, even these studies were not immune to concerns, particularly regarding randomization processes and adherence to intervention protocols. In contrast, studies with higher risk of bias faced significant challenges, including variability in intervention administration, lack of control over confounding variables, and issues with handling missing data. These factors introduced uncertainty into the findings, necessitating cautious interpretation. Despite these limitations, this meta-analysis is crucial for synthesizing existing evidence and identifying areas for future research of the effects of classical psychedelics on empathy. To improve the robustness and reliability of future studies on psychedelics and empathy, it is crucial to enhance methodological rigor by ensuring proper randomization, standardizing interventions, and minimizing dropout rates. Future research should also prioritize the inclusion of control groups and placebos, as well as the administration of consistent doses across participants, to facilitate more accurate comparisons. Placebocontrolled experimental studies are particularly important for controlling the potential influence of nonpharmacological factors, such as the environment and participant expectations, which can significantly impact outcomes. Additionally, incorporating objective measures and neuroimaging techniques will help to explore the neural correlates of empathy under the influence of psychedelics. Longitudinal clinical research, especially in clinical populations, is needed to investigate the therapeutic mechanisms of psychedelics like psilocybin and to further assess the role of empathy in symptom alleviation. Addressing these methodological considerations will be essential for advancing our understanding of how classical psychedelics influence empathy across diverse contexts and for enhancing the generalizability and application of findings in therapeutic settings. Despite all these limitations it is important to note that our meta-analysis used a comprehensive and systematic approach to gather and analyze data. We examined the Multifaceted Empathy Test (MET), a standardized tool to measure empathy, across various studies. The use of the MET tool across all studies provided a consistent and specific measurement of empathy, enhancing the comparability and reliability of our results, which was the strength of this meta-analysis. Moreover, our meta-analysis has a high ecological value since we took into consideration different settings and ways of administration of these substances. Specifically, the setting of a ceremony in cases of an ayahuasca ceremony and different physical, social and cultural environments in which the drug was taken may change the mental experience of their effect. For example, one study reported that the ceremonies were held in a supportive group environment, which may affect the experience of the participants positively and may have contributed to improvements in the effectcompared to studies that examined the effects of the substance on individuals who were alone or with a therapist when they were administered the substance. Therefore, conducting a meta-analysis that analyzes results across these different settings contributes to understanding the effect of these substances on empathy. Moreover, the research includes different classical psychedelics, which enables us to generalize beyond one specific substance. The way psychedelics are reported in studies can be varied and complex due to differences in the types, doses, and timing of administration. In our research, the sample sizes ranged from 19 to 55), ages from 25 to over 40 years, and dosage levels of psychedelics are different and depend on the type of drugs. These results offer new possibilities for therapeutic applications. Empathy is crucial in psychotherapy because enhanced empathy can deepen the therapist-patient connection and improve therapy outcomes. Specifically in disorders characterized by empathy deficits, such as certain personality disorders, psychedelics might aid in developing better social skills and emotional connections. Indeed, early studies suggested the use of psychedelic drugs as a treatment for criminals with antisocial personality disorders and psychopaths. Importantly, we would like to acknowledge that all of the studies examined in this meta-analysis were done on healthy participants. Studying the effects of these substances on clinical populations could provide valuable insights into their therapeutic potential, such as depression and anxiety. Moreover, to better understand the neurological effects of psychedelics, it is important to examine their acute and prolonged neural effect on empathy using imaging techniques such as electroencephalography (EEG) and functional magnetic resonance imaging (fMRI). These methods will provide insight into the neurological correlates of the empathy-enhancing effects of psychedelics. Lastly, exploring individual differences in the subjective response to psychedelics and addressing ethical considerations surrounding their use are also crucial aspects of this field of research. In conclusion, continued research on the effects of classical psychedelics on empathy is necessary for understanding their complex effects and potential therapeutic applications in fostering empathy and promoting prosocial behavior. Continued research in this domain is not just a scientific imperative but also a moral one, as it promises to look for new therapeutic modalities that could profoundly benefit individuals and society at large.
Create a free account to open full-text PDFs.
Halberstadt, A. L., Geyer, M. A. · Neuropharmacology (2011)
Johnson, M. W., Griffiths, R. R. · Neurotherapeutics (2017)
Thomas, G., Lucas, P., Rielle Capler, N. et al. · Current Drug Abuse Reviews (2013)
Oehen, P., Traber, R., Widmer, V. et al. · Journal of Psychopharmacology (2012)
Nour, M. R., Evans, J., Nutt, D. J. et al. · Frontiers in Human Neuroscience (2016)
Mason, N. L., Mischler, E., Uthaug, M. V. et al. · Journal of Psychoactive Drugs (2019)
Pokorny, T., Preller, K. H., Kometer, M. et al. · International Journal of Neuropsychopharmacology (2017)
Domínguez-Clavé, E., Soler, J., Elices, M. et al. · Brain Research Bulletin (2016)
Dolder, P. C., Schmid, Y., Müller, F. et al. · Neuropsychopharmacology (2016)
Aday, J. S., Bloesch, E. K., Wood, J. R. et al. · Reviews In The Neuroscience (2021)
Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J. et al. · Journal of Neuroscience (2013)
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)
Maclean, K. A., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2011)
Rodríguez-Fornells, A., Ribeiro, S., Sanches, R. F. et al. · European Neuropsychopharmacology (2015)
Johnstad, P. G. · Journal of Psychoactive Drugs (2020)
´dric, C., Hysek, M., Schmid, Y. et al. · Social Cognitive and Affective Neuroscience (2013)
Holze, F., Avedisian, I., Varghese, N. et al. · Frontiers in Pharmacology (2021)
Rocha, J. M., Rossi, G. N., de Lima Osório, F. et al. · Journal of Clinical Psychopharmacology (2021)